Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Palliative Medicine
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hardy, J. R
Right arrow Articles by Stone, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hardy, J. R
Right arrow Articles by Stone, P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

A prospective survey of the use of dexamethasone on a palliative care unit

Janet R Hardy

Elizabeth Rees

Julie Ling

Rachel Burman

London and Surrey

David Feuer

Karen Broadley

Patrick Stone

One hundred and six consecutive patients started on glucocorticosteroids (steroids) according to a defined prescription policy were surveyed each week to document the indications for use, any beneficial effect, any toxicity incurred and the reason for stopping. All patients had advanced malignant disease and survived for a median of 40.5 days (range 1–398+ days) from the start of steroid treatment. Fifty-seven per cent of patients completed three or more assessments. The most common specific indications for starting steroids were spinal cord compression, cerebral metastases, lymphangitis carcinomatosa and intestinal obstruction. The most common non-specific indications were anorexia, nausea, low mood, pain and vomiting. The median duration of steroid use was 21.5 days (range 1–89 days). The most common reason for the discontinuation of steroids was death or deteriorating condition. Symptom scores improved at some stage for the majority of patients started on steroids for anorexia, nausea, pain, low mood, vomiting and weakness but not in patients complaining of dyspnoea or poor mobility. The most common side-effects that were most probably attributable to steroid therapy were oral candidosis and proximal myopathy. The benefits of steroids when used according to defined guidelines were thought to outweigh toxicity.

Key Words: corticosteroids • palliative care • prescription guidelines

Palliative Medicine, Vol. 15, No. 1, 3-8 (2001)
DOI: 10.1191/026921601673324846


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Palliat MedHome page
S Lundstrom, C. Furst, M Friedrichsen, and P Strang
The existential impact of starting corticosteroid treatment as symptom control in advanced metastatic cancer
Palliative Medicine, March 1, 2009; 23(2): 165 - 170.
[Abstract] [PDF]


Home page
JCOHome page
E. Bruera, B. El Osta, V. Valero, L. C. Driver, B.-L. Pei, L. Shen, V. A. Poulter, and J. L. Palmer
Donepezil for Cancer Fatigue: A Double-Blind, Randomized, Placebo-Controlled Trial
J. Clin. Oncol., August 10, 2007; 25(23): 3475 - 3481.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
S. Yennurajalingam and E. Bruera
Palliative Management of Fatigue at the Close of Life: "It Feels Like My Body Is Just Worn Out"
JAMA, January 17, 2007; 297(3): 295 - 304.
[Abstract] [Full Text] [PDF]


Home page
AM J HOSP PALLIAT CAREHome page
P. Rousseau
Sudden withdrawal of corticosteroids: A commentary
American Journal of Hospice and Palliative Medicine, May 1, 2004; 21(3): 169 - 171.
[PDF]


Home page
Palliat MedHome page
P. Robson and A. Hughes
Glucocorticoids in palliative medicine: is osteoporosis a problem?
Palliative Medicine, October 1, 2003; 17(7): 645 - 646.
[PDF]


Home page
Palliat MedHome page
S. Lundstrom and C. J. Furst
Symptoms in advanced cancer: relationship to endogenous cortisol levels
Palliative Medicine, September 1, 2003; 17(6): 503 - 508.
[Abstract] [PDF]


Home page
Palliat MedHome page
A N Davies, S. Brailsford, and D. Beighton
Corticosteroids and oral candidosis
Palliative Medicine, September 1, 2001; 15(6): 521 - 521.
[PDF]


Home page
Palliat MedHome page
C. Gannon
The prescription of steroids in the terminal phase
Palliative Medicine, September 1, 2001; 15(6): 522 - 522.
[PDF]